Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
Psychoradiology · 02.03.2023 · 3
DOI: 10.1093/psyrad/kkad009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Psychoradiology, online erschienen am 22.06.2023. Verfasst von Chun Dang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Periodical Press, West China Hospital, Sichuan University, Chengdu 610000, China. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province, China Postdoctoral Science Foundation.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most common cause of dementia. Neuropathological changes in AD patients occur up to 10–20 years before the emergence of clinical symptoms. Specific diagnosis and appropriate intervention strategies are crucial during the phase of mild cognitive impairment (MCI) and AD. The detection of biomarkers has emerged as a promising tool for tracking the efficacy of potential therapies, making an early disease diagnosis, and prejudging treatment prognosis. Specifically, multiple neuroimaging modalities, including magnetic resonance imaging (MRI), positron emission tomography, optical imaging, and single photon emission-computed tomography, have provided a few potential biomarkers for clinical application. The MRI modalities described in this review include structural MRI, functional MRI, diffusion tensor imaging, magnetic resonance spectroscopy, and arterial spin labelling. These techniques allow the detection of presymptomatic diagnostic biomarkers in the brains of cognitively normal elderly people and might also be used to monitor AD disease progression after the onset of clinical symptoms. This review highlights potential biomarkers, merits, and demerits of different neuroimaging modalities and their clinical value in MCI and AD patients. Further studies are necessary to explore more biomarkers and overcome the limitations of multiple neuroimaging modalities for inclusion in diagnostic criteria for AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Periodical Press, West China Hospital, Sichuan University, Chengdu 610000, China.
- Department of Neurology, Chifeng University of Affiliated Hospital, Chifeng 024000, China.
- Department of Neurology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
- Department of General Surgery, Chengdu Integrated Traditional Chinese Medicine and Western Medicine Hospital, Chengdu 610000, China.
ORCID-Profile: Chun Dang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
- China Postdoctoral Science Foundation
- Postdoctoral Foundation of Hei Long Jiang Province
- Sichuan Provincial Administration of Traditional Chinese Medicine
- Natural Science Foundation of Inner Mongolia
Zitieren
APA
Dang, C., Wang, Y., Li, Q., & Lu, Y. (2023). Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers. Psychoradiology, 3. https://doi.org/10.1093/psyrad/kkad009
Vancouver
Dang C, Wang Y, Li Q, Lu Y. Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers. Psychoradiology. 2023;3. doi:10.1093/psyrad/kkad009
BibTeX
@article{Dang2023,
author = {Dang, Chun and Wang, Yanchao and Li, Qian and Lu, Yaoheng},
title = {Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers},
journal = {Psychoradiology},
year = {2023},
volume = {3},
doi = {10.1093/psyrad/kkad009}
}
EUVIMED